"In an impromptu discussion following the annual meeting, MNTA’s CMO, Jim Roach, expressed serious doubt that the FDA will approve Teva’s low-volume formulation based on the data reported in #msg-50939364."
MNTA haven't been able to figure out when/if their own products would get approval or when with any accuracy (it's always "very soon" with them) So I find it arrogant and foolish for them to comment on their competitions chances and timing for approval.
My question is whether there is likely to be any causation related to the volume of the injection and the site injuries so common in Copaxone treated patients.
In fact, the opposite could turn out to be true, ie smaller volumes of higher concentration could cause more site damage.
I have no idea which might be true. But there is some inference supporting the former given that TEVA is reducing the volume.
News 
Market Data 
Discover 
AI
